Quantum Genomics receives a 3 M EUR financing (AcT)

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces today that it received a medium-term financing of 3 M€, through a bond issue.

This strengthens the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension (read the press release of November 17, 2014: Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension).

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).

Contacts